MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

16.87 11.94

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.77

Max

17.1

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.2M -12M
Angestellte	37
EBITDA	-2.1M -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+121.61% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-57M 1.3B
Vorheriger Eröffnungskurs	4.93
Vorheriger Schlusskurs	16.87

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

3.165 / 3.5827 Unterstützung & Widerstand

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Apr. 2026, 23:26 UTC

Heiße Aktien

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. Apr. 2026, 20:41 UTC

Wichtige Markttreiber

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. Apr. 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. Apr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. Apr. 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. Apr. 2026, 22:08 UTC

Ergebnisse

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Health Care Roundup: Market Talk

16. Apr. 2026, 20:49 UTC

Ergebnisse

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. Apr. 2026, 20:43 UTC

Ergebnisse

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Netflix Says Engagement Quality Hits New High -- Market Talk

16. Apr. 2026, 20:30 UTC

Heiße Aktien

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. Apr. 2026, 20:25 UTC

Ergebnisse

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:23 UTC

Ergebnisse

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. Apr. 2026, 20:19 UTC

Ergebnisse

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

121.61% Vorteil

12-Monats-Prognose

Durchschnitt 33.33 USD 121.61%

Hoch 42 USD

Tief 27 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

3.165 / 3.5827Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.